Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: Analysis of the southwest oncology group database for antimicrotubule-platinum therapy

Clinical Lung Cancer

Volumn 14, Issue 6, 2013, Pages 627-635

  Kelly, Karen ^a   Chansky, Kari ^b   Mack, Philip C ^a   Lara, Primo N ^a   Hirsch, Fred R ^c   Franklin, Wilbur A ^d   Wozniak, Antoinette J ^e   Edelman, Martin J ^f   Williamson, Stephen K ^g   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

^g UNIVERSITY OF KANSAS   (United States)

Author keywords

Chemotherapy outcomes; Histology; Lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

CHEMOTHERAPY OUTCOMES; HISTOLOGY; LUNG CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ONCOLOGY NURSING; PACLITAXEL; PLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOUTHWESTERN UNITED STATES; TAXOIDS; TUBULIN MODULATORS; VINBLASTINE;

EID: 84887224108     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.06.010     Document Type: Article

References (28)

1. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer New Engl J Med 346 2002 92 98
2. J. Sigmond, H.H. Backu, and D. Wouters Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDR human colon cancer cells is associated with thymidylate synthase overexpression Biochem Pharmacol 66 2003 431 438
3. E. Giovannetti, V. Mey, and S. Nannizzi Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells Mol Pharmacol 68 2005 110 118
4. G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine to cisplatin plus pemetrexed in chemotherapy naive patients with advanced non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
5. G. Scagliotti, T. Brodowicz, and F.A. Shepherd Treatment by histology interaction analysis in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer J Thorac Oncol 4 2011 64 70
6. M.A. Socinski, I. Bondarenko, and N.A. Karaseva Weekly nab-Paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial J Clin Oncol 30 2012 2055 2062
7. N. Imielinski, A.H. Berger, and P.S. Hammerman Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing Cell 150 2012 1107 1120
8. Cancer Genome Atlas Network, P.S. Hammerman, and D.N. Hayes Comprehensive genomic characterization of squamous cell lung cancers Nature 489 2012 519 525
9. A.J. Wozniak, J.J. Crowley, and S.P. Balcerzak Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study J Clin Oncol 16 1998 2459 2465
10. K. Kelly, J. Crowley, and P.A. Bunn Jr. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
11. M.J. Edelman, J.I. Clark, and K. Chansky Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel Clin Cancer Res 10 2004 5022 5026
12. S.K. Williamson, J.J. Crowley, and P.N. Lara Jr. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003 J Clin Oncol 23 2005 9097 9104
13. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
14. T. Hoang, S. Dahlberg, and J.H. Schiller Does histology predict survival of advanced non-small cell lung cancer (NSCLC) treated with standard platin-based chemotherapy? Retrospective analysis of E1594 J Thorac Oncol 4 Supp1 2009 S493 S494
15. G.V. Scagliotti, F. De Marinis, and M. Rinaldi The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial J Thorac Oncol 4 2009 1568 1571
16. K. Clements, M.D. Naaciniak, and D. Farles The impact of tumor histology on survival among elderly chemotherapy-treated patients with stage IIIB/IV NSCLC J Clin Oncol 26 2008 (Abstract #19067)
17. A. Ardizzoni, L. Boni, and M. Tiseo Cisplatin-versus carboplatin-based chemotherapy in first line treatment of advanced non-small cell lung cancer: an individual patient data meta-analysis J Natl Cancer Inst 99 2007 845 857
18. F.R. Hirsch, A. Spreafico, and S. Novello The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review J Thorac Oncol 3 2008 1468 1481
19. D.R. Gandara, P.P. Grimminger, and P.C. Mack Histology-and gene-related associations of ERCC1, RRM1, and TS biomarkers in 1802 patients with NSCLC: implications for therapy J Clin Oncol 28 2010 (Abstract #7513)
20. H.L. Zhang, L. Ruan, and L.M. Zeng Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis Lung Cancer 77 2012 9 15
21. A.C. Vilmar, E. Santoni-Rugiu, and J.B. Sorensen Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial Clin Cancer Res 17 2011 5205 5214
22. T. Reiman, R. Lai, and A.S. Veillard Cross-validation study of class III beta-tubulin as a predictive marker of benefit from adjuvant chemotherapy in resected non-small cell lung cancer: Analysis of four randomized trials Ann Oncol 23 2012 86 93
23. R.N. Pillai, S.A. Brodie, and G.L. Sica CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC Clin Cancer Res 19 2013 1603 1611
24. J. Patel, M.A. Socinski, and E.B. Garon A randomized, open-label, phase 3 superiority study of pemetrexed (Pem)+ carboplatin (Cb) + bevacizumab (B) followed by maintenance Pem + B versus Paclitaxel + Cb + B followed by maintenance B in patients with stage IIIB or IV non-squamous non-small cell lung cancer J Thorac Oncol 7 2012 S336
25. B.H. Gronberg, R.M. Bremnes, and O. Flotten Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared with Gemcitibine Plus Carboplatin As First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer J Clin Oncol 27 2009 3217 3224
26. A.R. Hanauske, U. Eismann, and O. Oberschmidt In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression Invest New Drugs 25 2007 417 423
27. D.C. Christoph, B.R. Asuncion, and B. Hassan Investigation of folate receptor alpha and thymidylate synthase proteins expression in metastatic non-small cell lung cancer patients treated with pemetrexed-based chemotherapy J Thorac Oncol 7 2012 S211
28. N.I. Lindeman, P.T. Cagle, and M.B. Beasley Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology J Thorac Oncol 8 2013 823 859